Brokerages expect that Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) will report $45.95 million in sales for the current fiscal quarter, Zacks reports. Five analysts have issued estimates for Alnylam Pharmaceuticals’ earnings. The lowest sales estimate is $38.80 million and the highest is $56.70 million. Alnylam Pharmaceuticals reported sales of $29.91 million during the same quarter last year, which would suggest a positive year-over-year growth rate of 53.6%. The firm is expected to announce its next quarterly earnings report on Thursday, August 1st.
On average, analysts expect that Alnylam Pharmaceuticals will report full year sales of $186.06 million for the current year, with estimates ranging from $113.10 million to $236.00 million. For the next fiscal year, analysts expect that the firm will post sales of $422.33 million, with estimates ranging from $321.46 million to $514.80 million. Zacks’ sales averages are an average based on a survey of analysts that follow Alnylam Pharmaceuticals.
Alnylam Pharmaceuticals (NASDAQ:ALNY) last issued its quarterly earnings results on Wednesday, May 1st. The biopharmaceutical company reported ($1.73) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($2.20) by $0.47. Alnylam Pharmaceuticals had a negative return on equity of 55.33% and a negative net margin of 929.51%. The company had revenue of $33.29 million for the quarter, compared to the consensus estimate of $21.60 million. During the same quarter in the prior year, the business earned ($1.22) EPS. Alnylam Pharmaceuticals’s revenue was up 52.0% on a year-over-year basis.
Shares of NASDAQ ALNY opened at $70.80 on Friday. The company has a current ratio of 9.33, a quick ratio of 9.12 and a debt-to-equity ratio of 0.20. Alnylam Pharmaceuticals has a 1-year low of $60.27 and a 1-year high of $124.21. The stock has a market cap of $7.54 billion, a price-to-earnings ratio of -9.35 and a beta of 2.59.
In other news, Director Philip A. Sharp sold 15,000 shares of the stock in a transaction dated Monday, April 15th. The stock was sold at an average price of $88.23, for a total value of $1,323,450.00. Following the transaction, the director now owns 250,633 shares in the company, valued at approximately $22,113,349.59. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CEO John Maraganore sold 49,457 shares of the stock in a transaction dated Wednesday, May 15th. The shares were sold at an average price of $70.00, for a total value of $3,461,990.00. Following the completion of the transaction, the chief executive officer now owns 239,450 shares in the company, valued at approximately $16,761,500. The disclosure for this sale can be found here. Corporate insiders own 3.60% of the company’s stock.
Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. Gilder Gagnon Howe & Co. LLC grew its stake in Alnylam Pharmaceuticals by 3.5% during the 1st quarter. Gilder Gagnon Howe & Co. LLC now owns 987,770 shares of the biopharmaceutical company’s stock worth $92,307,000 after buying an additional 33,174 shares during the last quarter. Metropolitan Life Insurance Co NY grew its stake in Alnylam Pharmaceuticals by 3.5% during the 1st quarter. Metropolitan Life Insurance Co NY now owns 6,557 shares of the biopharmaceutical company’s stock worth $612,000 after buying an additional 221 shares during the last quarter. FMR LLC grew its stake in Alnylam Pharmaceuticals by 5.2% during the 1st quarter. FMR LLC now owns 15,945,666 shares of the biopharmaceutical company’s stock worth $1,490,122,000 after buying an additional 791,113 shares during the last quarter. Maverick Capital Ltd. grew its stake in Alnylam Pharmaceuticals by 14.5% during the 1st quarter. Maverick Capital Ltd. now owns 3,210,387 shares of the biopharmaceutical company’s stock worth $300,011,000 after buying an additional 406,436 shares during the last quarter. Finally, Schonfeld Strategic Advisors LLC grew its stake in Alnylam Pharmaceuticals by 318.0% during the 1st quarter. Schonfeld Strategic Advisors LLC now owns 62,700 shares of the biopharmaceutical company’s stock worth $5,860,000 after buying an additional 47,700 shares during the last quarter. Institutional investors and hedge funds own 89.78% of the company’s stock.
Alnylam Pharmaceuticals Company Profile
Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing RNA interference (RNAi) therapeutics. The company's pipeline of investigational RNAi therapeutics focus on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system/ocular diseases.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Alnylam Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.